High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma

Meghan Karuturi; Chitra Hosing; Michelle Fanale; L. Jeffrey Medeiros; Amin M. Alousi; Marcos J. de Lima; Muzaffar H. Qazilbash; Partow Kebriaei; Anas Younes; Issa Khouri; Borje S. Andersson; Richard Champlin; Paolo Anderlini; Uday Popat

doi:10.1016/j.bbmt.2013.03.008

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma

Meghan Karuturi, Chitra Hosing, Michelle Fanale, L. Jeffrey Medeiros, Amin M. Alousi, Marcos J. de Lima, Muzaffar H. Qazilbash, Partow Kebriaei, Anas Younes, Issa Khouri, Borje S. Andersson, Richard Champlin, Paolo Anderlini, Uday Popat

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.

Original language	English (US)
Pages (from-to)	991-994
Number of pages	4
Journal	Biology of Blood and Marrow Transplantation
Volume	19
Issue number	6
DOIs	https://doi.org/10.1016/j.bbmt.2013.03.008
State	Published - Jun 2013

Keywords

Autologous stem cell transplantation
Chemosensitive
Hodgkin Lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma
Relapse

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2013.03.008

Cite this

Karuturi, M., Hosing, C., Fanale, M., Medeiros, L. J., Alousi, A. M., de Lima, M. J., Qazilbash, M. H., Kebriaei, P., Younes, A., Khouri, I., Andersson, B. S., Champlin, R., Anderlini, P., & Popat, U. (2013). High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 19(6), 991-994. https://doi.org/10.1016/j.bbmt.2013.03.008

Karuturi, M , Hosing, C, Fanale, M, Medeiros, LJ , Alousi, AM, de Lima, MJ, Qazilbash, MH , Kebriaei, P, Younes, A, Khouri, I, Andersson, BS, Champlin, R, Anderlini, P & Popat, U 2013, 'High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma', Biology of Blood and Marrow Transplantation, vol. 19, no. 6, pp. 991-994. https://doi.org/10.1016/j.bbmt.2013.03.008

@article{445c255e4689439d9120bf170647f25b,

title = "High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma",

abstract = "Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.",

keywords = "Autologous stem cell transplantation, Chemosensitive, Hodgkin Lymphoma, Nodular lymphocyte predominant Hodgkin lymphoma, Relapse",

author = "Meghan Karuturi and Chitra Hosing and Michelle Fanale and Medeiros, {L. Jeffrey} and Alousi, {Amin M.} and {de Lima}, {Marcos J.} and Qazilbash, {Muzaffar H.} and Partow Kebriaei and Anas Younes and Issa Khouri and Andersson, {Borje S.} and Richard Champlin and Paolo Anderlini and Uday Popat",

year = "2013",

month = jun,

doi = "10.1016/j.bbmt.2013.03.008",

language = "English (US)",

volume = "19",

pages = "991--994",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma

AU - Karuturi, Meghan

AU - Hosing, Chitra

AU - Fanale, Michelle

AU - Medeiros, L. Jeffrey

AU - Alousi, Amin M.

AU - de Lima, Marcos J.

AU - Qazilbash, Muzaffar H.

AU - Kebriaei, Partow

AU - Younes, Anas

AU - Khouri, Issa

AU - Andersson, Borje S.

AU - Champlin, Richard

AU - Anderlini, Paolo

AU - Popat, Uday

PY - 2013/6

Y1 - 2013/6

N2 - Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.

AB - Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.

KW - Autologous stem cell transplantation

KW - Chemosensitive

KW - Hodgkin Lymphoma

KW - Nodular lymphocyte predominant Hodgkin lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84877912785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877912785&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.03.008

DO - 10.1016/j.bbmt.2013.03.008

M3 - Article

C2 - 23507470

AN - SCOPUS:84877912785

SN - 1083-8791

VL - 19

SP - 991

EP - 994

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 6

ER -

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this